- Previous Close
0.0100 - Open
0.0100 - Bid 0.0050 x --
- Ask 0.0150 x --
- Day's Range
0.0100 - 0.0100 - 52 Week Range
0.0050 - 0.1050 - Volume
10,000 - Avg. Volume
546 - Market Cap (intraday)
317,624 - Beta (5Y Monthly) 6.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company's pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinical need for rational enhanced caloric intake and micronutrient supplementation. It also develops edible oils, moringa, hops, cannabis sativa, pharma, sea cucumber, ginseng, and functional fungi ingredients; and anti-virals and phytomedicinalization. In addition, the company flash-freezes active ingredients, oils, and oleoresins for use as ingredients in food, nutraceuticals, and other consumer products. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. is based in Coquitlam, Canada.
www.arevlifesciences.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AREVF
View MorePerformance Overview: AREVF
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AREVF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AREVF
View MoreValuation Measures
Market Cap
317.62k
Enterprise Value
419.46k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
62.01
Price/Book (mrq)
--
Enterprise Value/Revenue
82.07
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.42%
Return on Equity (ttm)
--
Revenue (ttm)
7.21k
Net Income Avi to Common (ttm)
-239.54k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-83.09k